Opinion|Videos|December 15, 2023
KRYSTAL-1: Follow-Up Data on Adagrasib Monotherapy in Patients with Advanced/Metastatic KRASG12C Mutated NSCLC
Author(s)Narjust Florez, MD
Dr Narjust Florez discusses the KRYSTAL-1 trial, focusing on the effectiveness and side effects of adagrasib in treating patients with NSCLC and KRASG12C mutations, and noting their impact on progression-free and overall survival.
Advertisement
Episodes in this series
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Related Content
Advertisement
Advertisement
Trending on CancerNetwork
1
A Look Back on the Top 10 Oncology Interviews in 2025
2
Spotlighting the Top 10 FDA Oncology Approvals in 2025
3
Zovegalisib Combo Confers Efficacy Benefit in PIK3CA-Mutated Breast Cancer
4
‘Relatively Low’ AEs Noted With Durvalumab/FLOT in Gastric/GEJ Cancer
5